MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model

作者：Mukherjee P^*; Pathangey L B; Bradley J B; Tinder T L; Basu G D; Akporiaye E T; Gendler S J

来源：Vaccine, 2007, 25(9): 1607-1618.

DOI：10.1016/j.vaccine.2006.11.007

• MUC1
• CpG ODN
• GM-CSF
• colon cancer

A MUC1-based vaccine was used in a preclinical model of colon cancer. The trial was conducted in a MUC1-tolerant immune competent host injected with MC38 colon cancer cells expressing MUC1. The vaccine included: MHC class I-restricted MUC1 peptides, MHC class II-restricted pan-helper-peptide, Unmethylated CpG oligodeoxynucleotide, and granulocyte macrophage-colony stimulating factor. Immunization was successful in breaking MUC1 self-tolerance, and in eliciting a robust anti-tumor response. The vaccine stimulated IFN gamma-producing CD4(+) helper and CD8(+) cytotoxic T cells against MUC1 and other undefined MC38 tumor antigens. In the prophylactic setting, immunization caused complete rejection of tumor cells, while in the therapeutic regimen, tumor burden was significantly reduced.

• 出版日期2007-2-19